JP6882996B2 - オキシステロールおよびそれらの使用の方法 - Google Patents
オキシステロールおよびそれらの使用の方法 Download PDFInfo
- Publication number
- JP6882996B2 JP6882996B2 JP2017568208A JP2017568208A JP6882996B2 JP 6882996 B2 JP6882996 B2 JP 6882996B2 JP 2017568208 A JP2017568208 A JP 2017568208A JP 2017568208 A JP2017568208 A JP 2017568208A JP 6882996 B2 JP6882996 B2 JP 6882996B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- compound
- pharmaceutically acceptable
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)C(CC[C@@](C)[C@@](CC1)[C@@](C)(CC2)[C@@]1C1[C@]2[C@@](C)(CC[C@@](C2)OC([C@](C)*N)=O)C2=CC1)OC([C@](C)N)=O Chemical compound CC(C)C(CC[C@@](C)[C@@](CC1)[C@@](C)(CC2)[C@@]1C1[C@]2[C@@](C)(CC[C@@](C2)OC([C@](C)*N)=O)C2=CC1)OC([C@](C)N)=O 0.000 description 7
- GQQFPIFERAETTE-UHFFFAOYSA-N C=C(C(O)=O)NCl Chemical compound C=C(C(O)=O)NCl GQQFPIFERAETTE-UHFFFAOYSA-N 0.000 description 1
- AWYRCQSXEMLVGF-MTBAOGSRSA-N CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O Chemical compound CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O AWYRCQSXEMLVGF-MTBAOGSRSA-N 0.000 description 1
- XGUXPCFYBZEUCL-XOLAWMNISA-N CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OS(O)(=O)=O Chemical compound CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OS(O)(=O)=O XGUXPCFYBZEUCL-XOLAWMNISA-N 0.000 description 1
- RDELIRROTRZWDQ-VNPDGQOTSA-N CC(C)[C@@](CC[C@@H](C)[C@@H](CC1)C[C@@H]1C(C)CC=C(C)C)(O)S=C Chemical compound CC(C)[C@@](CC[C@@H](C)[C@@H](CC1)C[C@@H]1C(C)CC=C(C)C)(O)S=C RDELIRROTRZWDQ-VNPDGQOTSA-N 0.000 description 1
- IZUQQAFAZNMAKK-QHLOWXICSA-N CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC(CN)=O Chemical compound CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC(CN)=O IZUQQAFAZNMAKK-QHLOWXICSA-N 0.000 description 1
- JOYQWTTWWVZXLS-BTXZHLCBSA-N CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC([C@H](C(C)C)N)=O Chemical compound CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC([C@H](C(C)C)N)=O JOYQWTTWWVZXLS-BTXZHLCBSA-N 0.000 description 1
- NGIVIKXHOHDJHX-OETAEELFSA-N CCC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O Chemical compound CCC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O NGIVIKXHOHDJHX-OETAEELFSA-N 0.000 description 1
- NCVRLCMZCVGWAI-OHAFEYBFSA-N CCC[C@H](CCC1)[C@H]2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 Chemical compound CCC[C@H](CCC1)[C@H]2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 NCVRLCMZCVGWAI-OHAFEYBFSA-N 0.000 description 1
- KGAIAHQGWDSWHR-SBFPOUOMSA-N CCC[C@]12[C@@H](C)CC(C)(C)[C@H]1[C@H]2C Chemical compound CCC[C@]12[C@@H](C)CC(C)(C)[C@H]1[C@H]2C KGAIAHQGWDSWHR-SBFPOUOMSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N C[C@@H](C(O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(O)=O)NC(OC(C)(C)C)=O QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- ALPMHTYWWGCBOJ-VGXOWKQNSA-N C[C@H](CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)OC(CCC(O)=O)=O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)OC(CCC(O)=O)=O)C2=CC1 ALPMHTYWWGCBOJ-VGXOWKQNSA-N 0.000 description 1
- BLSDTZSARUNYKA-RKWHMGMVSA-N C[C@H](CCC(C)(C)OC(CCC(O)=O)=O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)OC(CCC(O)=O)=O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 BLSDTZSARUNYKA-RKWHMGMVSA-N 0.000 description 1
- BLSDTZSARUNYKA-VGXOWKQNSA-N C[C@H](CCC(C)(C)OC(CCC(O)=O)=O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)OC(CCC(O)=O)=O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 BLSDTZSARUNYKA-VGXOWKQNSA-N 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N O=C(CC1)OC1=O Chemical compound O=C(CC1)OC1=O RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021001453A JP7410062B2 (ja) | 2015-07-06 | 2021-01-07 | オキシステロールおよびそれらの使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189065P | 2015-07-06 | 2015-07-06 | |
| US62/189,065 | 2015-07-06 | ||
| PCT/US2016/041160 WO2017007832A1 (en) | 2015-07-06 | 2016-07-06 | Oxysterols and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001453A Division JP7410062B2 (ja) | 2015-07-06 | 2021-01-07 | オキシステロールおよびそれらの使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519329A JP2018519329A (ja) | 2018-07-19 |
| JP2018519329A5 JP2018519329A5 (OSRAM) | 2019-07-25 |
| JP6882996B2 true JP6882996B2 (ja) | 2021-06-02 |
Family
ID=57686058
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568208A Active JP6882996B2 (ja) | 2015-07-06 | 2016-07-06 | オキシステロールおよびそれらの使用の方法 |
| JP2021001453A Active JP7410062B2 (ja) | 2015-07-06 | 2021-01-07 | オキシステロールおよびそれらの使用の方法 |
| JP2022107293A Active JP7478190B2 (ja) | 2015-07-06 | 2022-07-01 | オキシステロールおよびそれらの使用の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001453A Active JP7410062B2 (ja) | 2015-07-06 | 2021-01-07 | オキシステロールおよびそれらの使用の方法 |
| JP2022107293A Active JP7478190B2 (ja) | 2015-07-06 | 2022-07-01 | オキシステロールおよびそれらの使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10696712B2 (OSRAM) |
| EP (2) | EP3319610A4 (OSRAM) |
| JP (3) | JP6882996B2 (OSRAM) |
| AU (2) | AU2016289965B2 (OSRAM) |
| CA (1) | CA2991311C (OSRAM) |
| HK (1) | HK1255500A1 (OSRAM) |
| MA (1) | MA42409A (OSRAM) |
| WO (1) | WO2017007832A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012304412A1 (en) | 2011-09-08 | 2014-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT2968369T (pt) | 2013-03-13 | 2018-12-05 | Sage Therapeutics Inc | Esteroides neuroativos e métodos para o seu uso |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2963938C (en) * | 2014-10-07 | 2023-10-24 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| CN113292623A (zh) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| PT3319612T (pt) * | 2015-07-06 | 2021-08-24 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| BR112019008032A2 (pt) | 2016-10-18 | 2019-09-03 | Sage Therapeutics, Inc. | oxiesteróis e métodos de uso dos mesmos |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN110628737B (zh) * | 2019-10-14 | 2022-06-07 | 南京农业大学 | 一个调控黄瓜矮化性状相关基因及其应用 |
| CA3223179A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) * | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (OSRAM) * | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) * | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) * | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) * | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) * | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) * | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) * | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) * | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| DE3664909D1 (en) * | 1985-05-30 | 1989-09-14 | Taisho Pharmaceutical Co Ltd | Vitamin d3 derivatives |
| JPS62187485A (ja) * | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0701444B1 (en) | 1993-05-24 | 2010-04-07 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| BR9506779A (pt) | 1994-02-14 | 1997-10-14 | Cocensys Inc | Composto composição farmacéutica método para modular o complexo ionóforo receptor gaba-cloreto em um paciente animal pela ligação ao sitio neuroesteróide no dito complexo método para tratar ou evitar estresse ou ansiedade em um paciente animal método para aliviar ou evitar isônia pms ou pnd em um paciente animal método para tratar ou evitar perturbacões na disposicão de ánimo em um paciente animal e método para induzir anestesia em um paciente animal |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| JPH08268917A (ja) * | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| PL185523B1 (pl) | 1995-06-06 | 2003-05-30 | Cocensys Inc | Neuroaktywne steroidy z grupy pochodnych androstanu i pregnanu oraz kompozycja farmaceutyczna |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| CA2224866A1 (en) | 1995-06-23 | 1997-01-09 | Novo Nordisk A/S | Meiosis regulating compounds |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) * | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) * | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) * | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| TW200300078A (en) | 2001-11-08 | 2003-05-16 | Univ Chicago | Method of treating disorder related to high cholesterol concentration |
| EP1461028A4 (en) | 2001-12-07 | 2007-07-25 | Univ California | TREATMENT FOR AGE-RELATED MACULAR AGENCY |
| ATE424211T1 (de) | 2002-03-27 | 2009-03-15 | Phytopharm Plc | Therapeutische verwendung von sapogeninen |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| JP2009528291A (ja) | 2006-02-27 | 2009-08-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | オキシステロール化合物及びヘッジホッグ経路 |
| WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| CN101842355A (zh) | 2007-06-20 | 2010-09-22 | 奥斯拜客斯制药有限公司 | 作为纤维化抑制剂的取代的n-芳基吡啶酮 |
| EP2207542A2 (en) | 2007-11-06 | 2010-07-21 | N.V. Organon | A method of hormone suppression in humans |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088408A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor antagonists for the treatment of neurological conditions |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| CA2784119A1 (en) * | 2009-12-15 | 2011-06-23 | Neurop, Inc. | Compounds for the treatment of neurologic disorders |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) * | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| AU2012304412A1 (en) * | 2011-09-08 | 2014-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT2766380T (pt) | 2011-10-14 | 2019-07-29 | Sage Therapeutics Inc | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| KR102400891B1 (ko) | 2012-12-18 | 2022-05-20 | 워싱톤 유니버시티 | 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법 |
| CN105073119A (zh) | 2013-01-23 | 2015-11-18 | 司菲埃拉制药私人有限公司 | 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物 |
| WO2014120786A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| HK1220472A1 (zh) * | 2013-03-13 | 2017-05-05 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| PT2968369T (pt) | 2013-03-13 | 2018-12-05 | Sage Therapeutics Inc | Esteroides neuroativos e métodos para o seu uso |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3166613A4 (en) | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| US10016095B2 (en) * | 2014-10-03 | 2018-07-10 | Progressive International Corporation | Salad spinner |
| CA2963938C (en) * | 2014-10-07 | 2023-10-24 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| PT3319612T (pt) | 2015-07-06 | 2021-08-24 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| CN113292623A (zh) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| BR112019027458A2 (pt) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
| US20190160078A1 (en) | 2017-11-10 | 2019-05-30 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
-
2016
- 2016-07-06 EP EP16821920.2A patent/EP3319610A4/en not_active Withdrawn
- 2016-07-06 HK HK18114684.2A patent/HK1255500A1/zh unknown
- 2016-07-06 JP JP2017568208A patent/JP6882996B2/ja active Active
- 2016-07-06 WO PCT/US2016/041160 patent/WO2017007832A1/en not_active Ceased
- 2016-07-06 US US15/742,422 patent/US10696712B2/en active Active
- 2016-07-06 EP EP23199636.4A patent/EP4316591A3/en active Pending
- 2016-07-06 MA MA042409A patent/MA42409A/fr unknown
- 2016-07-06 CA CA2991311A patent/CA2991311C/en active Active
- 2016-07-06 AU AU2016289965A patent/AU2016289965B2/en active Active
-
2020
- 2020-05-20 US US16/879,460 patent/US20210101925A1/en not_active Abandoned
-
2021
- 2021-01-07 JP JP2021001453A patent/JP7410062B2/ja active Active
- 2021-08-20 AU AU2021218227A patent/AU2021218227B2/en active Active
-
2022
- 2022-05-20 US US17/749,976 patent/US20230047157A1/en not_active Abandoned
- 2022-07-01 JP JP2022107293A patent/JP7478190B2/ja active Active
-
2024
- 2024-06-18 US US18/746,388 patent/US20250154192A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3319610A4 (en) | 2019-03-06 |
| NZ738582A (en) | 2024-10-25 |
| AU2021218227A1 (en) | 2021-09-09 |
| HK1255500A1 (zh) | 2019-08-16 |
| US20230047157A1 (en) | 2023-02-16 |
| CA2991311C (en) | 2025-05-06 |
| US20180201643A1 (en) | 2018-07-19 |
| US20210101925A1 (en) | 2021-04-08 |
| US20250154192A1 (en) | 2025-05-15 |
| AU2016289965A1 (en) | 2018-01-18 |
| CA2991311A1 (en) | 2017-01-12 |
| JP7478190B2 (ja) | 2024-05-02 |
| EP4316591A2 (en) | 2024-02-07 |
| JP2018519329A (ja) | 2018-07-19 |
| JP2022130668A (ja) | 2022-09-06 |
| JP2021063118A (ja) | 2021-04-22 |
| EP4316591A3 (en) | 2024-04-24 |
| AU2021218227B2 (en) | 2023-08-03 |
| AU2016289965B2 (en) | 2021-09-09 |
| MA42409A (fr) | 2018-05-16 |
| JP7410062B2 (ja) | 2024-01-09 |
| WO2017007832A1 (en) | 2017-01-12 |
| EP3319610A1 (en) | 2018-05-16 |
| US10696712B2 (en) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6882996B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| JP7602513B2 (ja) | オキシステロールおよびそれらの使用の方法 | |
| AU2021218230B2 (en) | Oxysterols and methods of use thereof | |
| HK40107350A (en) | Oxysterols and methods of use thereof | |
| HK40053565A (en) | Oxysterols and methods of use thereof | |
| HK1247564B (en) | Oxysterols and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200928 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210408 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6882996 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |